Woodline Partners LP Theravance Biopharma, Inc. Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.39 - $10.22 $17.8 Million - $21.7 Million	-2,123,619 Reduced 94.66%	119,854 $1.22 Million
Q2 2022 Aug 15, 2022	BUY	$8.41 - $10.34 $7.71 Million - $9.48 Million	916,820 Added 69.11%	2,243,473 $20.3 Million
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $6.26 Million - $9.74 Million	751,540 Added 130.68%	1,326,653 $12.7 Million
Q4 2021 Feb 14, 2022	SELL	$7.42 - $11.05 $10.4 Million - $15.5 Million	-1,404,017 Reduced 70.94%	575,113 $6.36 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $10.9 Million - $23.1 Million	1,604,218 Added 427.89%	1,979,130 $14.6 Million
Q2 2021 Aug 16, 2021	BUY	$14.52 - $22.46 $5.44 Million - $8.42 Million	374,912 New	374,912 $5.44 Million

126

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $649M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.